Preliminary analyses of efficacy and safety of Cyberknife stereotactic body radiotherapy for 26 patients with recurrent cholangiocellular carcinoma after surgery
Liu Zhuang1, Qiu Minghan2, Wu Zhiqiang1, Meng Maobin1, Wang Huanhuan1, Wang Zhongqiu1, Dong Yang1, Yuan Zhiyong1, Wang Ping1
1Department of Radiation Oncology, Cancer Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin′s Clinical Research Center for Cancer, Tianjin 300060,China; 2Tianjin People's Hospital Cancer Center,Third Department of Cancer Therapy, Tianjin 300121, China
Abstract：Objective To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) using Cyberknife in the treatment of patients with recurrent cholangiocellular carcinoma (RCC) after surgery. Methods Clinical data of 26 patients with recurrent RCC after surgery undergoing Cyberknife SBRT from 2010 to 2015 were retrospectively analyzed. The median recurrence time was 10 months (range 2.0-63.0 months) and the median tumor diameter was 2.8 cm (range 1.2-4.8 cm). The median prescription dose/fraction was 45 Gy/5f (range 40-50 Gy/3-8 f). The tumor progression was evaluated based on enhanced CT or MRI. Overall survival (OS),progression-free survival (PFS) and local control rate (LC) were analyzed by Kaplan-Meier method. Toxicity was assessed using the common terminology criteria for adverse events version 4.0. Results For the entire cohort, the median OS and PFS were 13.5 months and 6.5 months at a median follow-up of 29.3 months (range 2.1-62.0 months). The 1-and 2-year OS and PFS rates were 52% and 21% as well as 28% and 15%,respectively. Among them,4 patients (4/26,15%) were recurrent in situ after SBRT. Three patients experienced grade Ⅲ adverse reactions including 1 case of gastrointestinal reaction, 1 case of liver dysfunction and 1 case of biliary tract infection. Only 1 patient suffered from ≥grade IV gastrointestinal bleeding during the advanced stage. Conclusions SBRT using Cyberknife is a safe and effective treatment for patients with recurrent RCC after surgery. The adverse reactions can be tolerated by patients.
Liu Zhuang,Qiu Minghan,Wu Zhiqiang et al. Preliminary analyses of efficacy and safety of Cyberknife stereotactic body radiotherapy for 26 patients with recurrent cholangiocellular carcinoma after surgery[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 518-521.
[1]Blechacz B. Cholangiocarcinoma:current knowledge and new developments[J]. Gut liver,2017,11(1):13-26. DOI:10.5009/gnl15568. [2]Esnaola NF,Meyer JE,Karachristos A,et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma[J]. Cancer,2016,122(9):1349-1369. DOI:10.1002/cncr.29692. [3]Park HM,Yun SP,Lee EC,et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery[J]. Ann Surg Oncol,2016,23(13):4392-4400. DOI:10.1245/s10434-016-5454-2. [4]Bridgewater J,Galle PR,Khan SA,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol,2014,60(6):1268-1289. DOI:10.1016/j.jhep.2014.01.021. [5]Miyazaki Y,Kokudo T,Amikura K,et al. Survival of surgery for recurrent biliary tract cancer:a single-center experience and systematic review of literature[J]. Japan J Clin Oncol,2017,47(3):206-212. DOI:10.1093/jjco/hyw182. [6]Spolverato G,Kim Y,Alexandrescu S,et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J]. Ann Surg Oncol,2016,23(1):235-243. DOI:10.1245/s10434-015-4642-9. [7]Takahashi Y,Ebata T,Yokoyama Y,et al. Surgery for recurrent biliary tract cancer:A single-center experience with 74 consecutive resections[J]. Ann Surg,2015,262(1):121-129. DOI:10.1097/SLA.0000000000000827. [8]Yoh T,Hatano E,Seo S,et al. Long-term survival of recurrent intrahepatic cholangiocarcinoma:the impact and selection of repeat surgery[J]. World J Surg,2018,42(6):1848-1856. DOI:10.1007/s00268-017-4387-7. [9]Fu Y,Yang W,Wu W,et al. Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma[J]. Chin J Cancer Res,2011,23(4):295-300. DOI:10.1007/s11670-011-0295-9. [10]Kim JH,Won HJ,Shin YM,et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection[J]. Eur J Radiol,2011,80(3):e221-225. DOI:10.1016/j.ejrad.2010.09.019. [11]Zhang SJ,Hu P,Wang N,et al. Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2013,20(11):3596-3602. DOI:10.1245/s10434-013-3035-1. [12]Kuhlmann JB,Blum HE. Locoregional therapy for cholangiocarcinoma[J]. Cur Opin Gastroenterol,2013,29(3):324-328. DOI:10.1097/MOG.0b013e32835 d9 dea. [13]Kopek N,Holt MI,Hansen AT,et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma[J]. Radiother Oncol,2010,94(1):47-52. DOI:10.1016/j.radonc.2009.11.004. [14]Mahadevan A,Dagoglu N,Mancias J,et al. Stereotactic body radiotherapy (sbrt) for intrahepatic and hilar cholangiocarcinoma[J]. J Cancer,2015,6(11):1099-1104. DOI:10.7150/jca.13032. [15]Dang YZ,Huang SG,Lu WL,et al. Curative effect of stereotactic body radiotherapy on hepatic hilar carcinoma[J]. Mol Clin Oncol,2014,2(6):1135-1138. DOI:10.3892/mco.2014.395. [16]Tao R,Krishnan S,Bhosale PR,et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma:A retrospective dose response analysis[J]. J Clin Oncol,2016,34(3):219-226. DOI:10.1200/JCO.2015.61.3778. [17]Gkika E,Hallauer L,Kirste S,et al. Stereotactic body radiotherapy (sbrt) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. BMC Cancer,2017,17(1):781. DOI:10.1186/s12885-017-3788-1. [18]Jung DH,Kim MS,Cho CK,et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma[J]. Radiat Oncol J,2014,32(3):163-169. DOI:10.3857/roj.2014.32.3.163. [19]Valle J,Wasan H,Palmer DH,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. New Engl J Med,2010,362(14):1273-1281. DOI:10.1056/NEJMoa0908721. [20]Yoo C,Han B,Kim HS,et al. Multicenter phase ii study of oxaliplatin,irinotecan,and s-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer[J]. Cancer Res Treat,2018,50(4):1324-1330. DOI:10.4143/crt.2017.526. [21]Polistina FA,Guglielmi R,Baiocchi C,et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable,non-metastatic,locally advanced hilar cholangiocarcinoma. Results of a five year experience[J]. Radiother Oncol,2011,99(22):120-123. DOI:10.1016/j.radonc.2011.05.016. [22]Van den Begin R,Engels B,Boussaer M,et al. Motion management during sbrt for oligometastatic cancer:results of a prospective phase ii trial[J]. Radiother Oncol,2016,119(3):519-524. DOI:10.1016/j.radonc.2016.04.020. [23]Velec M,Moseley JL,Dawson LA,et al. Dose escalated liver stereotactic body radiation therapy at the mean respiratory position[J]. Int J Radiat Oncol Biol Phys,2014,89(5):1121-1128. DOI:10.1016/j.ijrobp.2014.04.051. [24]Iizuka Y,Matsuo Y,Ishihara Y,et al. Dynamic tumor-tracking radiotherapy with real-time monitoring for liver tumors using a gimbal mounted linac[J]. Radiother Oncol,2015,117(3):496-500. DOI:10.1016/j.radonc.2015.08.033.
2019, Vol. 28 
